Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Monopar Therapeutics Inc (MNPR) has provided an update.
Monopar Therapeutics Inc. has announced the commencement of its Phase 1 dosimetry clinical trial for MNPR-101-Zr, a new radiopharmaceutical imaging agent designed to diagnose advanced cancers. Patients are currently being recruited for this innovative trial, which marks a significant step forward in cancer imaging techniques.
Learn more about MNPR stock on TipRanks’ Stock Analysis page.